Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 4/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745333 | 0.93 | CNR2 (0.56) | CNR2CNR1NPC1GAAAPEX1 | |
| SCHEMBL30904706 | 0.85 | CNR1 (0.53) | CNR2CNR1NPC1GAAALDH1A1 | |
| SCHEMBL3697820 | 0.84 | APEX1 (0.55) | NPC1GAAAPEX1MAPTALDH1A1 | |
| SCHEMBL20569640 | 0.83 | CNR2 (0.51) | CNR2CNR1NPC1GAAAPEX1 | |
| SCHEMBL11098187 | 0.78 | CYP1A2 (0.59) | NPC1GAAALDH1A1TSHR | |
| SCHEMBL7056983 | 0.76 | APEX1 (0.47) | NPC1GAAAPEX1MAPTALDH1A1 | |
| SCHEMBL22700957 | 0.76 | NPC1 (0.47) | CNR2CNR1NPC1GAAAPEX1 | |
| SCHEMBL20569856 | 0.75 | KDM4E (0.58) | CNR2CNR1GAAMAPTALDH1A1 | |
| SCHEMBL740153 | 0.74 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL1128490 | 0.74 | FABP4 (0.50) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | CNR2 4083/4885CNR1 2843/4885NPC1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.